Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | SRC | P12931 | 2/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | FLT1 | P17948 | 2/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.46 |
| ▸ | XDH | P47989 | 3/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745771 | 0.85 | LMNA (0.56) | EGFRSRCPDPK1ERBB2LMNA | |
| SCHEMBL15265722 | 0.77 | EGFR (0.61) | EGFRKDRSRCPDPK1ABL1 | |
| SCHEMBL1893862 | 0.77 | EGFR (0.61) | EGFRKDRSRCPDPK1ABL1 | |
| SCHEMBL4745310 | 0.77 | RET (0.54) | EGFRKDRSRCPDPK1ABL1 | |
| SCHEMBL4742854 | 0.76 | EGFR (0.62) | EGFRKDRSRCABL1FLT1 | |
| SCHEMBL4742038 | 0.76 | EGFR (0.62) | EGFRKDRSRCABL1FLT1 | |
| SCHEMBL15263519 | 0.75 | SRC (0.61) | EGFRKDRSRCABL1FLT1 | |
| SCHEMBL1893875 | 0.75 | SRC (0.61) | EGFRKDRSRCABL1FLT1 | |
| SCHEMBL4744333 | 0.75 | EGFR (0.54) | EGFRKDRSRCPDPK1MAP2K1 | |
| SCHEMBL2063734 | 0.73 | MAP2K1 (0.68) | EGFRKDRSRCMAP2K1ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008109613-A1 | BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | EGFR 3929/4885KDR 3906/4885SRC 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.